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Cytogenetic response induced by interferon alpha in the myeloproliferative disorder with eosinophilia, T cell lymphoma and the chromosomal translocation t(8;13)(p11;q12) TO 
THE EDITOR
A distinct biphenotypic hematological malignancy has been described in a subset of patients with a myeloproliferative disorder (MPD) characterized by myeloid hyperplasia and eosinophilia, a T cell lymphoblastic lymphoma (T-LBL), and a chromosomal translocation t(8;13)(p11;q12) in bone marrow (BM), and in some cases, also in lymph nodes (LN). 1,2 The description of other cases with similar morphological and clinical features with different translocations involving chromosome band 8p11 has led to the proposal of terming this entity as the '8p11 myeloproliferative syndrome'. 3 Moreover, a report of two cases with myeloid malignancy and a t(8;13) with a precursor T and B cell acute lymphoblastic leukemia (ALL) raises the question whether this cytogenetic abnormality results in a pluripotential stem cell capable of myeloid and lymphoid differentiation. 4, 5 At the molecular level, the t(8;13) has been recently characterized. The 8p11 breakpoint was found to be distinct from the t(8;16) and t(8;22) translocations, and therefore the MOZ gene was not rearranged. 5, 6 Despite all these patients being treated with diverse chemotherapy regimens, evolution to acute myeloid leukemia (AML) was rapid in most cases and thus optimal therapy for this entity is to be established. We report a patient with the t(8;13) syndrome who responded successfully to interferon alpha (IFN-␣) for 1 year. Subsequent allogeneic peripheral blood stem cell transplantation (PBSCT) was performed and currently she remains in complete remission 26 months after diagnosis.
Correspondence: JA Martinez-Climent Received 16 January 1998; accepted 2 February 1998 A 56-year-old female was referred for evaluation of a short history of weakness and leukocytosis. On physical examination she presented splenomegaly with no other remarkable features. A CBC showed RBC 8.23 × 10 6 /l, Hb 15.9 g/L, platelets 546 × 10 9 /l and WBC 85.9 × 10 9 /l with a differential count of 20% eosinophils and 6% basophils. LDH was 495 mU/ml and FAL 10. BM aspirate was markedly hypercellular with myeloid hyperplasia, 22% of eosinophils and 1% basophils. Cytogenetic analysis of BM identified a t(8;13)(p11;q12) in 25 of 25 metaphases karyotyped with additional cytogenetic abnormalities in 28% of cells. BCR/ABL-p210 rearrangement was not detected by RT-PCR. The patient was trated with cytarabine 10 mg/m 2 /day for 3 weeks and IFN-␣ 5 × 10 6 U/m 2 /day with a marked clinical and hematological response. Three months later, she developed massive generalized peripheral lymphadenopathy with WBC 7.0 × 10 9 /l and a normal BM film. Aspiration cytology and biopsy of a lymph node resected from the cervical area performed 1 week apart revealed a diffuse infiltration by a small lymphoid cell population with scant cytoplasm and round nuclei, with no myeloid infiltration. Immunophenotype analysis of lymphoid cells was: CD2 97%, CD3 10%, CD5 93%, CD4 91%, CD8 39%, CD13 1%, CD33 4%. In the lymph node aspiration cytology large immature lymphoid cells were seen and numerous mature eosinophils were scattered among the malignant cells. Therefore, a diagnosis of T cell lymphoma was made. TCR and IgH genes showed a germline configuration. IFN-␣ therapy was then continued and the lymphadenopathy resolved progressively in 2 months. A partial cytogenetic response was seen after 1 year of IFN-␣: only 70% of BM cells had a t(8;13), and moreover, secondary chromo-somal abnormalities were absent in all cells. The patient underwent an allogeneic HLA-identical PBSCT. Conditioning regimen consisted of busulphan and cyclophosphamide and the transplant course was uneventful. At days +30 and +240 she displayed normal BM karyotypes.
All 10 patients described previously with the MPD with t(8;13) were treated with aggressive chemotherapy for T-LBL, AML, or ALL. No patient was treated with IFN-␣. Although eight achieved complete remission, evolution to AML was seen in most patients following a 'chronic phase' of less than 1 year. Only three patients are alive in continuous complete remission after allogeneic (two patients) or autologous transplantation (one), 14 weeks, 16 months, and 9 months, respectively. [1] [2] [3] [4] [5] A T-LBL has been found in eight cases of the t(8;13) syndrome, and another patient had lymphadenopathy with immature hemopoietic cell and eosinophilic infiltration. In six cases, the lymphoma and the myeloid malignancy presented simultaneously whereas in two other patients the lymphoma developed after presentation of the MPD, 7 weeks and 6 months later. In our case, massive lymphadenopathy was first seen after diagnosis. A complete clinical and hematologic remission including resolution of lymphadenopathy was achieved after IFN-␣ therapy, as well as a partial cytogenetic response. IFN-␣ is the treatment of choice for patients with chronic myeloid leukemia and it is also used in polycythemia vera (PV) and essential thrombocythemia. 7 In a patient with PV and chromosomal abnormalities, a complete cytogenetic response was achieved after 6 months of IFN-␣. 8 In a chronic MPD associated with a t(5;21)(q31;q22), complete but transient hematologic and cytogenetic remission was induced by IFN-␣ after 27 months. 9 A cytogenetic remission was also induced by IFN-␣ in a patient with an unusual MPD with trisomy 8. 10 However, the therapeutic role of IFN-␣ in nonHodgkin's lymphomas is controversial, because while it improves the response rate and remission duration in follicular lymphomas, in high-grade lymphomas the results have been disappointing. 7 The mechanism of therapeutic action of IFN-␣ in the malignant process is complex. A direct antiproliferative effect has been observed in susceptible cells resulting in inhibition of tumorigenesis. There is also a modulation of the immune response, which may contribute to its antitumor effect. Another basis may exist in the induction of cell differentiation, which can re-establish normal hemopoiesis. 7 We hypothesize that in our case IFN-␣ could target a hematologic pluripotential malignant stem cell, inhibiting simultaneously myeloid and T cell proliferation and incuding differentiation of malignant cells re-establishing in part normal diploid cells.
In summary, IFN-␣ was an effective therapy for the myeloid malignancy while it prevented growth of the malignant T cell clone. Thus, IFN-␣ could be of benefit in the management of newly diagnosed patients with the t(8;13) syndrome.
